Ian Smith is Chief Executive Officer of Stoke Therapeutics, Inc. (STOK). The company reported total compensation of $27,031,655 for fiscal year 2025.
| Salary | $170,625 |
|---|---|
| Bonus | $1,197,125 |
| Stock awards | $11,590,000 |
| Option awards | $14,035,067 |
| Non-equity incentive plan | $0 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $38,838 |
| Total | $27,031,655 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Stoke Therapeutics, Inc. filed April 22, 2026, accession 0001193125-26-170362.
| Peer-group chief executive median | $2,978,038 |
|---|---|
| Difference from that median | $24,053,617 |
| Percentile within the disclosed peer group | 99th |
| Peers with a disclosed figure | 12 |
Medians and percentiles are computed across the peer group Stoke Therapeutics, Inc. discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Ian Smith this page | Chief Executive Officer | $27,031,655 |
| Edward Kaye | Former Chief Executive Officer | $3,234,043 |
| Jason Hoitt | Chief Patient Officer | $2,269,955 |
| Thomas Leggett | Chief Financial Officer | $1,830,375 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Stoke Therapeutics, Inc. compensation brief.
Ian Smith's compensation sits inside Stoke Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.